NZ608380A - Pharmaceutical composition comprising deferasirox - Google Patents

Pharmaceutical composition comprising deferasirox

Info

Publication number
NZ608380A
NZ608380A NZ608380A NZ60838011A NZ608380A NZ 608380 A NZ608380 A NZ 608380A NZ 608380 A NZ608380 A NZ 608380A NZ 60838011 A NZ60838011 A NZ 60838011A NZ 608380 A NZ608380 A NZ 608380A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutical composition
deferasirox
iron overload
chronic iron
disclosure
Prior art date
Application number
NZ608380A
Other languages
English (en)
Inventor
Geena Malhotra
Dr Shrinivas Madhukar Purandare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44802316&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ608380(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of NZ608380A publication Critical patent/NZ608380A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ608380A 2010-10-01 2011-09-30 Pharmaceutical composition comprising deferasirox NZ608380A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2750MU2010 2010-10-01
PCT/GB2011/001428 WO2012042224A2 (en) 2010-10-01 2011-09-30 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
NZ608380A true NZ608380A (en) 2014-10-31

Family

ID=44802316

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ608380A NZ608380A (en) 2010-10-01 2011-09-30 Pharmaceutical composition comprising deferasirox

Country Status (18)

Country Link
US (3) US20140147503A1 (https=)
EP (1) EP2621471A2 (https=)
JP (1) JP2013538845A (https=)
KR (1) KR20140011300A (https=)
CN (1) CN103209687A (https=)
AP (1) AP3578A (https=)
AU (1) AU2011309872B2 (https=)
BR (1) BR112013007276A2 (https=)
CA (1) CA2812505A1 (https=)
EC (1) ECSP13012534A (https=)
IL (1) IL225457A (https=)
MX (1) MX2013003522A (https=)
MY (1) MY165826A (https=)
NZ (1) NZ608380A (https=)
PE (2) PE20170468A1 (https=)
RU (1) RU2589842C2 (https=)
WO (1) WO2012042224A2 (https=)
ZA (1) ZA201302092B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2788300T3 (es) 2010-11-09 2020-10-21 Univ Cornell Regeneración hepática
MX2015003729A (es) 2012-11-12 2015-06-15 Cipla Ltd Composiciones farmaceuticas de dosis fija que comprende deferasirox y deferiprona.
ME03297B (me) * 2013-03-08 2019-07-20 Novartis Ag Oralne formulacije deferasiroksa
US10646452B2 (en) * 2013-03-15 2020-05-12 New Jersey Institute Of Technology System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process
HK1215191A1 (zh) * 2013-05-10 2016-08-19 Cipla Limited 低剂量医药组合物
TWI697337B (zh) * 2013-08-07 2020-07-01 學校法人近畿大學 奈米粒子或奈米粒子組成物之製造方法，及支架或球囊導管之製造方法
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
IN2014MU00303A (https=) * 2014-01-28 2015-09-11 Cipla Ltd
IN2014MU00916A (https=) * 2014-03-20 2015-09-25 Cipla Ltd
KR20160088965A (ko) * 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
CN107847490A (zh) 2015-06-17 2018-03-27 分散技术有限责任公司 改进的地拉罗司制剂及制备其的方法
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
US10888519B2 (en) * 2016-07-05 2021-01-12 Jubilant Generics Limited Immediate release pharmaceutical composition of iron chelating agents
CN107693516B (zh) * 2016-08-08 2020-06-26 上海宣泰医药科技有限公司 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
WO2018059922A1 (en) 2016-09-30 2018-04-05 Synthon B.V. Pharmaceutical composition comprising deferasirox
KR102771163B1 (ko) 2017-04-07 2025-02-25 엠에이에이 래보러토리스, 인코포레이티드 치료제의 용해도 및 생체이용률을 향상시키는 방법
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2019108156A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation comprising deferasirox in a film tablet form
US12419884B2 (en) 2018-08-06 2025-09-23 Brigham Young University Compositions and methods for treating iron overload
RS63725B1 (sr) 2020-05-18 2022-12-30 Orexo Ab Nova farmaceutska kompozicija za davanje leka
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
CN115400088B (zh) * 2022-09-06 2023-07-07 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1708343A1 (ru) * 1989-09-22 1992-01-30 Всесоюзный Научно-Исследовательский Институт Биотехнологии Способ получени твердых лекарственных форм
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
ATE419834T1 (de) * 2000-11-20 2009-01-15 Elan Pharma Int Ltd Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren
US6509380B1 (en) * 2001-12-14 2003-01-21 Marshall University Research Corporation Method of treating iron overload with acetaminophen
EP1490030B2 (en) * 2002-03-20 2010-07-14 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
GB0408078D0 (en) 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US7531351B2 (en) * 2004-06-14 2009-05-12 Probiogen Ag Liquid-gas-phase exposure reactor for cell culturing
EP1940360A1 (en) * 2005-10-19 2008-07-09 Novartis AG Dispersible tablets comprising deferasirox
US20090016359A1 (en) * 2007-07-11 2009-01-15 Samsung Electronics Co., Ltd. System and method for processing high definition video data to be transmitted over a wireless medium
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
EP2062572A1 (en) * 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
US20110097413A1 (en) * 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
WO2010035282A1 (en) 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox

Also Published As

Publication number Publication date
US20160324831A1 (en) 2016-11-10
KR20140011300A (ko) 2014-01-28
IL225457A (en) 2017-04-30
RU2589842C2 (ru) 2016-07-10
IL225457A0 (en) 2013-06-27
JP2013538845A (ja) 2013-10-17
AP2013006785A0 (en) 2013-04-30
AU2011309872A1 (en) 2013-04-11
WO2012042224A3 (en) 2012-08-09
WO2012042224A8 (en) 2013-04-11
AU2011309872B2 (en) 2014-09-04
US20180311216A1 (en) 2018-11-01
WO2012042224A2 (en) 2012-04-05
PE20140166A1 (es) 2014-02-17
MX2013003522A (es) 2013-05-22
CN103209687A (zh) 2013-07-17
US20140147503A1 (en) 2014-05-29
ECSP13012534A (es) 2013-10-31
CA2812505A1 (en) 2012-04-05
MY165826A (en) 2018-05-17
PE20170468A1 (es) 2017-04-26
EP2621471A2 (en) 2013-08-07
RU2013120275A (ru) 2014-11-20
BR112013007276A2 (pt) 2016-06-14
ZA201302092B (en) 2013-11-27
AP3578A (en) 2016-02-08

Similar Documents

Publication Publication Date Title
NZ608380A (en) Pharmaceutical composition comprising deferasirox
HK1208161A1 (en) Pharmaceutical nanoparticles showing improved mucosal transport
MX2021001091A (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
MX367712B (es) Composiciones y metodos de inhibicion de la corrosion.
PE20170312A1 (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso
MX384021B (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
IN2013MU03583A (https=)
HK1231471A1 (zh) 6-杂芳氧基-和6芳氧基-喹啉-2-甲酰胺及其用途
BR112013003969A2 (pt) composições de resina recicladas e dispositivos médicos descartáveis produzidos delas
WO2010087964A3 (en) Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
HK1215191A1 (zh) 低剂量医药组合物
IL201189A (en) Fluorization derivatifrone derivatives used as iron pellets in the treatment of neurodegenerative diseases, their preparation and their pharmaceutical preparations
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
HK1217092A1 (zh) 治疗性化合物及其用途
WO2010065329A3 (en) Nanoparticles for cancer treatment
NZ601000A (en) Calcipotriol monohydrate nanocrystals
WO2015159155A3 (en) Novel ademetionine formulations
PH12014501772A1 (en) Rapidly disintegrating tablet
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
NZ727834A (en) Fast acting orally disintegrating film
MY197917A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
MX360235B (es) Composicion para evitar o tratar osteoporosis y metodo de manufactura para el mismo.
WO2009126695A3 (en) Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes
WO2015073177A8 (en) Vaginal inserted estradiol pharmaceutical compositons and methods

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2016 BY CPA GLOBAL

Effective date: 20150821

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2017 BY CPA GLOBAL

Effective date: 20161203

LAPS Patent lapsed